Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney: Implications for renal safety

Toxicology in Vitro

Volumn 22, Issue 4, 2008, Pages 899-909

  Lühe, Anke ^a   Künkele, Klaus Peter ^b   Haiker, Monika ^a   Schad, Karen ^a   Zihlmann, Christine ^a   Bauss, Frieder ^b   Suter, Laura ^a   Pfister, Thomas ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

Bisphosphonates; Clodronate; Farnesyl diphosphate synthase; Ibandronate; Kidney; Mevalonate pathway; Nephrotoxicity; Nitrogen containing bisphosphonates; Non nitrogen containing bisphosphonates; Pamidronate; Renal; Zoledronate

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; GERANYLTRANSFERASE; IBANDRONIC ACID; MESSENGER RNA; MEVALONIC ACID; NITROGEN; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME INHIBITION; EXPLORATORY RESEARCH; IC 50; IN VITRO STUDY; KIDNEY; KIDNEY TUBULE CELL; MALE; NEPHROTOXICITY; NONHUMAN; PROTEIN EXPRESSION; RAT;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; CELL LINE; CLODRONIC ACID; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; GERANYLTRANSTRANSFERASE; HUMANS; IMIDAZOLES; INHIBITORY CONCENTRATION 50; KIDNEY; MALE; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER;

RATTUS;

EID: 41949138597     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tiv.2008.01.006     Document Type: Article

References (43)

1. Adachi J.D., Olszynski W.P., Hanley D.A., Hodsman A.B., Kendler D.L., Siminoski K.G., Brown J., Cowden E.A., Goltzman D., Ioannidis G., Josse R.G., Ste-Marie L.G., Tenenhouse A.M., Davison K.S., Blocka K.L., Pollock A.P., and Sibley J. Management of corticosteroid-induced osteoporosis. Seminars in Arthritis and Rheumatism 29 (2000) 228-251
2. Banerjee D., Asif A., Striker L., Preston R.A., Bourgoignie J.J., and Roth D. Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity. American Journal of Kidney Diseases 41 (2003) 1-6
3. Bauss F., and Body J.-J. Ibandronate in metastatic bone disease: a review of preclinical data. Anti-Cancer Drugs 16 (2005) 107-118
4. Benford H.L., Frith J.C., Auriola S., Monkkonen J., and Rogers M.J. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Molecular Pharmacology 56 (1999) 131-140
5. Bounameaux H.M., Schifferli J., Montani J.P., Jung A., and Chatelanat F. Renal failure associated with intravenous diphosphonates. Lancet 1 8322 (1983) 471
6. Caraglia M., Santini D., Marra M., Vincenzi B., Tonini G., and Budillon A. Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endrocrine-Related Cancer 13 (2006) 7-26
7. Chang J.T., Green L., and Beitz J. Renal failure with the use of zoledronic acid. The New England Journal of Medicine 349 (2003) 1676-1679
8. Chou T.C., and Talalay P. Quantitative analysis of dose effect relationship: the combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation 22 (1984) 27-54
9. Coxon F.P., Benford H.L., Russell R.G., and Rogers M.J. Protein synthesis is required for caspase activation and induction of apoptosis by bisphosphonate drugs. Molecular Pharmacology 54 (1998) 631-638
10. Coxon F.P., Helfrich M.H., Larijani B., Muzylak M., Dunford J.E., Marshall D., McKinnon A.D., Nesbitt S.A., Horton M.A., Seabra M.C., Ebetino F.H., and Rogers M.J. Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages. Journal of Biological Chemistry 276 (2001) 48213-48222
11. De Larco J.E., and Todaro G.J. Epithelioid and fibroblastic rat kidney cell clones: epidermal growth factor (EGF) receptors and the effect of mouse sarcoma virus transformation. Journal of Cellular Physiology 94 (1978) 335-342
12. Dunford J.E., Thompson K., Coxon F.P., Luckman S.P., Hahn F.M., Poulter C.D., Ebetino F.H., and Rogers M.J. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. Journal of Pharmacology and Experimental Therapeutics 296 (2001) 235-242
13. Dunford J.E., Rogers M.J., Ebetino F.H., Phipps R.J., and Coxon F.P. Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases. Journal of Bone and Mineral Research 21 (2006) 684-694
14. Fleisch H. Bisphosphonates in bone disease: from the laboratory to the patient. fourth ed. (2000), Academic Press, San Diego, USA
15. Haklai R., Weisz M.G., Elad G., Paz A., Marciano D., Egozi Y., Ben-Baruch G., and Kloog Y. Dislodgment and accelerated degradation of Ras. Biochemistry 37 (1998) 1306-1314
16. Hillner B.E., Ingle J.N., Chlebowski R.T., Gralow J., Yee G.C., Janjan N.A., Cauley J.A., Blumenstein B.A., Albain K.S., Lipton A., Brown S., and American Society of Clinical Oncology. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. Journal of Clinical Oncology 21 (2003) 4042-4057
17. Janssen van Doorn K., Neyns B., Van der Niepen P., and Verbeelen D. Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases. Nephron 89 (2001) 467-468
18. Lamson M.L., Fox J.L., and Higuchi WI. Calcium and 1-hydroxye-thylidene-1,1-bisphosphonic acid: polynuclear complex formation in the physiological range of pH. International Journal of Pharmaceutics 21 (1984) 143-154
19. Luckman S.P., Hughes D.E., Coxon F.P., Graham R., Russell G., and Rogers M.J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. Journal of Bone and Mineral Research 13 (1998) 581-589
20. Markowitz G.S., Fine P.L., Stack J.I., Kunis C.L., Radhakrishnan J., Palecki W., Park J., Nasr S.H., Hoh S., Siegel D.S., and D'Agati V.D. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney International 64 (2003) 281-289
21. Meunier P.J., Delmas P.D., Eastell R., McClung M.R., Papapoulos S., Rizzoli R., Seeman E., and Wasnich R.D. Diagnosis and management of osteoporosis in postmenopausal women: Clinical guidelines. International Committee for Osteoporosis Clinical Guidelines. Clinical Therapeutics 21 (1999) 1025-1044
22. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. Journal of Immunological Methods 65 (1983) 55-63
23. Muhlbauer R.C., Bauss F., Schenk R., Janner M., Bosies E., Strein K., and Fleisch H. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. Journal of Bone and Mineral Research 6 (1991) 1003-1011
24. Ostovic D., and Brenner G.S. Development of subcutaneous and intramuscular formulations of calcium alendronate salts. Drug Development and Industrial Pharmacy 21 (1995) 1157-1169
25. O'Sullivan T.L., Akbari A., and Cadnapaphornchai P. Acute renal failure associated with the administration of parenteral etidronate. Renal Failure 6 (1994) 767-773
26. Pfister T., Atzpodien E., and Bauss F. The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats. Toxicology 191 (2003) 159-167
27. Pfister T., Atzpodien E., Bohrmann B., and Bauss F. Acute renal effects of intravenous bisphosphonates in the rat. Basic and Clinical Pharmacology and Toxicology 97 (2005) 374-381
28. Reed B.C., and Rilling HC. Crystallization and partial characterization of prenyltransferase from avian liver. Biochemistry 14 (1975) 50-54
29. Rogers M.J. New insights into the molecular mechanisms of action of bisphosphonates. Current Pharmaceutical Design 9 (2003) 2643-2658
30. Rogers M.J., Gordon S., Benford H.L., Coxon F.P., Luckman S.P., Mönkkönen J., and Frith J.C. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88 Suppl. 12 (2000) 2961-2978
31. Rosen L.S., Gordon D., Kaminski M., Howell A., Belch A., Mackey J., Apffelstaedt J., Hussein M., Coleman RE., Reitsma D.J., Seaman J.J., Chen B.L., and Ambros Y. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. The Cancer Journal 7 (2001) 377-387
32. Rosen L.S., Gordon D., Tchekmedyian S., Yanagihara R., Hirsh V., Krzakowski M., Pawlicki M., de Souza P., Zheng M., Urbanowitz G., Reitsma D., and Seaman J.J. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - the zoledronic acid lung cancer and other solid tumors study group. Journal of Clinical Oncology 21 (2003) 3150-3157
33. Russell R.G.G., Croucher P.I., and Rogers M.J. Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporosis International Suppl. 2 (1999) S66-S80
34. Ryan M.J., Johnson G., Kirk J., Fuerstenberg S.M., Zager R.A., and Torok-Storb B. HK-2: an immortalized proximal tubule epithelial cell line from normal adult human kidney. Kidney International 45 (1994) 48-57
35. Scoppola A., and Galiano P. The mevalonate pathway and renal diseases: experimental and clinical implications. The International Journal of Artificial Organs 21 (1998) 243-246
36. Shipman C.M., Croucher P.I., Russell R.G., Helfrich M.H., and Rogers M.J. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Research 58 (1998) 5294-5297
37. Siris E.S. Goals of treatment for Paget's disease of bone. Journal of Bone and Mineral Research 14 (1999) 49-52
38. Suri S., Monkkonen J., Taskinen M., Pesonen J., Blank M.A., Phipps R.J., and Rogers M.J. Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity. Bone 29 (2001) 336-343
39. Tsai F.M., Shyu R.Y., and Jiang S.Y. RIG1 inhibits the Ras/mitogen-activated protein kinase pathway by suppressing the activation of Ras. Cellular Signaling 18 (2006) 349-358
40. Wakeling A.E. Inhibitors of growth factor signalling. Endocrine Related Cancer 12 Suppl. 1 (2005) S183-S187
41. Zager R.A., Shah V.O., Shah H.V., Zager P.G., Johnson A.C., and Hanson S. The mevalonate pathway during acute tubular injury: selected determinants and consequences. The American Journal of Pathology 161 (2002) 681-692
42. Zazgornik J., Grafinger P., Biesenbach G., Hubmann R., and Fridrik M. Acute renal failure and alendronate. Nephrology Dialysis Transplantation 12 (1997) 2797-2798
43. Zojer N., Keck A.V., and Pecherstorfer M. Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Safety 21 (1999) 389-406